

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplemental Table 1. Health related quality of life outcomes across racial/ethnic groups of childhood cancer survivors.

	White, non-Hispanic			Black, non-Hispanic				Hispanic			
	Mean	SE	P	Mean	SE	P	P*	Mean	SE	P	P*
Physical function											
Sibling	54.30	0.20	-	54.30	0.98	-	-	53.04	1.55	-	-
Survivor	51.83	0.09	-	49.72	0.57	-	-	50.27	0.43	-	-
Difference from sibling	-2.47	0.22	<0.001	-4.57	1.14	<0.001	0.07	-2.78	1.60	0.08	0.85
Survivor no CRT	52.32	0.10	-	51.01	0.60	-	-	50.77	0.48	-	-
Difference from sibling	-1.98	0.22	<0.001	-3.29	1.15	0.004	0.26	-2.27	1.62	0.16	0.86
Survivor with CRT	50.61	0.19	-	46.72	1.32	-	-	48.85	0.92	-	-
Difference from sibling	-3.69	0.28	<0.001	-7.58	1.66	<0.001	0.02	-4.19	1.80	0.02	0.78
Role physical											
Sibling	52.61	0.30	-	54.58	0.73	-	-	52.78	1.65	-	-
Survivor	51.29	0.10	-	49.46	0.52	-	-	49.49	0.45	-	-
Difference from sibling	-1.32	0.31	<0.001	-5.12	0.93	<0.001	<0.001	-3.29	1.70	0.05	0.25
Survivor no CRT	51.59	0.12	-	49.97	0.62	-	-	50.09	0.49	-	-
Difference from sibling	-1.01	0.32	0.001	-4.61	0.96	<0.001	<0.001	-2.69	1.70	0.11	0.33
Survivor with CRT	50.53	0.20	-	48.27	0.95	-	-	47.81	1.04	-	-
Difference from sibling	-2.08	0.36	<0.001	-6.32	1.28	<0.001	0.001	-4.97	1.95	0.01	0.14
Pain											
Sibling	50.43	0.18	-	51.36	0.95	-	-	50.02	0.93	-	-
Survivor	51.64	0.11	-	50.16	0.59	-	-	51.27	0.43	-	-
Difference from sibling	1.21	0.21	<0.001	-1.20	1.11	0.28	0.03	1.24	1.01	0.22	0.97
Survivor no CRT	51.73	0.13	-	50.64	0.70	-	-	51.18	0.49	-	-
Difference from sibling	1.30	0.22	<0.001	-0.72	1.18	0.54	0.09	1.16	1.04	0.27	0.90
Survivor with CRT	51.42	0.22	-	49.03	1.13	-	-	51.50	0.90	-	-
Difference from sibling	0.99	0.29	0.001	-2.33	1.47	0.11	0.03	1.48	1.27	0.25	0.71
General health											
Sibling	52.10	0.35	-	53.04	1.59	-	-	51.33	2.29	-	-
Survivor	48.72	0.12	-	48.07	0.60	-	-	47.15	0.50	-	-
Difference from sibling	-3.38	0.37	<0.001	-4.97	1.71	0.004	0.36	-4.18	2.34	0.07	0.74
Survivor no CRT	48.84	0.15	-	48.44	0.74	-	-	47.39	0.57	-	-
Difference from sibling	-3.26	0.37	<0.001	-4.61	1.78	0.009	0.46	-3.94	2.36	0.10	0.78
Survivor with CRT	48.42	0.24	-	47.22	1.00	-	-	46.48	1.02	-	-
Difference from sibling	-3.67	0.43	<0.001	-5.82	1.88	0.002	0.26	-4.85	2.50	0.05	0.64

Supplemental Table 1 continued. Health related quality of life outcomes across racial/ethnic groups of childhood cancer survivors.

Vitality											
Sibling	50.11	0.36	-	55.51	2.52	-	-	50.63	1.99	-	-
Survivor	49.23	0.11	-	50.19	0.59	-	-	49.70	0.47	-	-
Difference from sibling	-0.89	0.38	0.02	-5.32	2.61	0.04	0.09	-0.93	2.03	0.65	0.99
Survivor no CRT	49.31	0.14	-	50.18	0.70	-	-	49.69	0.51	-	-
Difference from sibling	-0.80	0.39	0.04	-5.34	2.63	0.04	0.09	-0.94	2.03	0.64	0.95
Survivor with CRT	49.01	0.23	-	50.22	1.12	-	-	49.74	1.08	-	-
Difference from sibling	-1.10	0.43	0.01	-5.29	2.79	0.06	0.14	-0.89	2.26	0.69	0.93
Role emotional											
Sibling	51.12	0.35	-	51.62	2.28	-	-	52.73	1.25	-	-
Survivor	50.45	0.11	-	49.66	0.52	-	-	48.62	0.50	-	-
Difference from sibling	-0.67	0.37	0.07	-1.96	2.37	0.41	0.59	-4.11	1.35	0.002	0.01
Survivor no CRT	50.47	0.13	-	49.59	0.61	-	-	48.72	0.59	-	-
Difference from sibling	-0.65	0.37	0.08	-2.04	2.38	0.39	0.56	-4.01	1.39	0.004	0.02
Survivor with CRT	50.38	0.21	-	49.84	1.01	-	-	48.33	0.93	-	-
Difference from sibling	-0.74	0.41	0.07	-1.78	2.54	0.48	0.68	-4.40	1.55	0.005	0.02
Social function											
Sibling	51.66	0.33	-	56.03	0.68	-	-	53.37	1.02	-	-
Survivor	50.19	0.11	-	48.93	0.53	-	-	48.04	0.48	-	-
Difference from sibling	-1.47	0.35	<0.001	-7.11	0.85	<0.001	<0.001	-5.33	1.13	<0.001	0.001
Survivor no CRT	50.39	0.13	-	49.18	0.63	-	-	48.18	0.55	-	-
Difference from sibling	-1.26	0.36	<0.001	-6.86	0.93	<0.001	<0.001	-5.18	1.16	<0.001	0.001
Survivor with CRT	49.69	0.21	-	48.33	0.99	-	-	47.62	0.99	-	-
Difference from sibling	-1.97	0.39	<0.001	-7.70	1.17	<0.001	<0.001	-5.75	1.43	<0.001	0.01
Mental health											
Sibling	50.70	0.35	-	55.75	1.42	-	-	52.93	1.40	-	-
Survivor	50.01	0.11	-	49.97	0.65	-	-	49.06	0.49	-	-
Difference from sibling	-0.69	0.36	0.06	-5.78	1.49	<0.001	0.001	-3.87	1.45	0.008	0.03
Survivor no CRT	50.08	0.14	-	50.18	0.75	-	-	48.82	0.54	-	-
Difference from sibling	-0.63	0.37	0.09	-5.57	1.59	<0.001	0.002	-4.11	1.47	0.005	0.02
Survivor with CRT	49.86	0.22	-	49.49	1.30	-	-	49.72	1.10	-	-
Difference from sibling	-0.84	0.41	0.04	-6.26	1.77	<0.001	0.003	-3.21	1.77	0.07	0.19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplemental Table 1 continued. Health related quality of life outcomes across racial/ethnic groups of childhood cancer survivors.

Physical component summary											
Sibling	53.74	0.28	-	53.48	0.85	-	-	52.04	1.96	-	-
Survivor	51.42	0.10	-	49.15	0.53	-	-	50.03	0.42	-	-
Difference from sibling	-2.32	0.30	<0.001	-4.33	1.00	<0.001	0.05	-2.01	1.99	0.31	0.88
Survivor no CRT	51.76	0.12	-	50.18	0.62	-	-	50.54	0.46	-	-
Difference from sibling	-1.98	0.30	<0.001	-3.29	1.05	0.002	0.23	-1.50	1.99	0.45	0.81
Survivor with CRT	50.56	0.21	-	46.72	1.01	-	-	48.63	0.95	-	-
Difference from sibling	-3.18	0.35	<0.001	-6.76	1.32	<0.001	0.008	-3.41	2.18	0.12	0.92
Mental component summary											
Sibling	49.61	0.38	-	55.52	1.37	-	-	52.42	1.40	-	-
Survivor	49.30	0.12	-	49.80	0.60	-	-	48.23	0.51	-	-
Difference from sibling	-0.31	0.39	0.43	-5.73	1.49	<0.001	<0.001	-4.19	1.47	0.004	0.01
Survivor no CRT	49.27	0.15	-	49.42	0.72	-	-	48.00	0.58	-	-
Difference from sibling	-0.35	0.40	0.39	-6.10	1.55	<0.001	<0.001	-4.42	1.50	0.003	0.008
Survivor with CRT	49.39	0.23	-	50.67	1.11	-	-	48.88	1.08	-	-
Difference from sibling	-0.22	0.44	0.61	-4.85	1.72	0.005	0.009	-3.55	1.76	0.04	0.07

SE, standard error; P=p-value for comparison to siblings of same race/ethnicity group; P*=p-value for comparison of the difference between survivor and sibling, referenced to non-Hispanic white survivor and sibling difference.

Adjusted for sex, age at follow-up, year at diagnosis, methotrexate exposure (intravenous and intrathecal), corticosteroid exposure and any CTCAE grade 3-4 chronic medical condition.

Supplemental Table 2. Emotional and health related quality of life outcomes across racial/ethnic groups of childhood cancer survivors with adjustment for current socioeconomic status.

Survivor-Sibling Difference	White, non-Hispanic		Black, non-Hispanic				Hispanic			
	Mean w/o SES	Mean w SES	Mean w/o SES	P	Mean w SES	P*	Mean w/o SES	P	Mean w SES	P*
Emotional Health										
Depression										
Overall	1.09	0.77	1.49	0.75	0.62	0.91	3.59	0.004	3.21	0.005
Survivor no CRT	0.91	0.74	1.26	0.79	0.62	0.93	3.52	0.004	3.23	0.007
Survivor with CRT	1.57	0.87	2.09	0.77	0.64	0.90	3.78	0.09	3.13	0.08
Anxiety										
Overall	0.09	-0.16	0.87	0.52	0.09	0.84	1.64	0.13	1.25	0.16
Survivor no CRT	0.29	0.14	1.19	0.48	0.61	0.72	1.67	0.19	1.34	0.25
Survivor with CRT	-0.47	-0.98	0.04	0.71	-1.23	0.86	1.54	0.14	0.97	0.14
Somatization										
Overall	1.03	0.78	3.00	0.11	2.28	0.22	1.43	0.67	1.07	0.75
Survivor no CRT	1.00	0.87	2.70	0.18	2.24	0.28	1.24	0.80	0.96	0.93
Survivor with CRT	1.12	0.52	3.76	0.11	2.39	0.25	2.03	0.47	1.44	0.46
Global severity index										
Overall	0.78	0.43	2.52	0.23	1.51	0.47	2.85	0.05	2.39	0.06
Survivor no CRT	0.74	0.54	2.33	0.30	1.58	0.49	2.76	0.06	2.39	0.09
Survivor with CRT	0.90	0.14	3.02	0.25	1.32	0.53	3.12	0.14	2.39	0.13
Health Related Quality of Life										
Physical function										
Overall	-2.47	-2.04	-4.57	0.07	-4.07	0.05	-2.78	0.85	-1.94	0.95
Survivor no CRT	-1.98	-1.76	-3.29	0.26	-3.14	0.18	-2.27	0.86	-1.61	0.93
Survivor with CRT	-3.69	-2.75	-7.58	0.02	-6.25	0.03	-4.19	0.78	-2.87	0.95
Role physical										
Overall	-1.32	-0.89	-5.12	<0.001	-4.72	<0.001	-3.29	0.25	-2.48	0.37
Survivor no CRT	-1.01	-0.78	-4.61	<0.001	-4.50	<0.001	-2.69	0.33	-2.04	0.48
Survivor with CRT	-2.08	-1.17	-6.32	0.001	-5.23	0.001	-4.97	0.14	-3.72	0.20
Pain										
Overall	1.21	1.55	-1.20	0.03	-0.41	0.09	1.24	0.97	1.61	0.95
Survivor no CRT	1.30	1.45	-0.72	0.09	-0.19	0.17	1.16	0.90	1.40	0.97
Survivor with CRT	0.99	1.79	-2.33	0.03	-0.93	0.06	1.48	0.71	2.19	0.75
General health										
Overall	-3.38	-2.92	-4.97	0.36	-4.48	0.40	-4.18	0.74	-3.20	0.91
Survivor no CRT	-3.26	-3.02	-4.61	0.46	-4.45	0.46	-3.94	0.78	-3.11	0.97
Survivor with CRT	-3.67	-2.68	-5.82	0.26	-4.56	0.35	-4.85	0.64	-3.44	0.77

Supplemental Table 2 continued. Emotional and health related quality of life outcomes across racial/ethnic groups of childhood cancer survivors with adjustment for current socioeconomic status.

Vitality										
Overall	-0.89	-0.57	-5.32	0.09	-5.26	0.09	-0.93	0.99	-0.30	0.89
Survivor no CRT	-0.80	-0.62	-5.34	0.09	-5.40	0.09	-0.94	0.95	0.38	0.91
Survivor with CRT	-1.10	-0.46	-5.29	0.14	-4.95	0.12	-0.89	0.93	-0.05	0.86
Role emotional										
Overall	-0.67	-0.27	-1.96	0.59	-1.69	0.55	-4.11	0.01	-3.35	0.02
Survivor no CRT	-0.65	-0.41	-2.04	0.56	-1.99	0.51	-4.01	0.02	-3.36	0.04
Survivor with CRT	-0.74	0.08	-1.78	0.68	-0.99	0.68	-4.40	0.02	-3.34	0.03
Social function										
Overall	-1.47	-0.97	-7.11	<0.001	-6.64	<0.001	-5.33	0.001	-4.38	0.005
Survivor no CRT	-1.26	-0.98	-6.86	<0.001	-6.68	<0.001	-5.18	0.001	-4.37	0.007
Survivor with CRT	-1.97	-0.94	-7.70	<0.001	-6.53	<0.001	-5.75	0.01	-4.40	0.02
Mental health										
Overall	-0.69	-0.35	-5.78	0.001	-5.61	<0.001	-3.87	0.03	-3.08	0.07
Survivor no CRT	-0.63	-0.44	-5.57	0.002	-5.54	0.001	-4.11	0.02	-3.39	0.05
Survivor with CRT	-0.84	-0.14	-6.26	0.003	-5.75	0.001	-3.21	0.19	-2.20	0.25
Physical component summary										
Overall	-2.32	-1.92	-4.33	0.05	-3.74	0.11	-2.01	0.88	-1.13	0.70
Survivor no CRT	-1.98	-1.78	-3.29	0.23	-3.06	0.28	-1.50	0.81	-0.77	0.62
Survivor with CRT	-3.18	-2.28	-6.76	0.008	-5.35	0.03	-3.41	0.92	-2.11	0.94
Mental component summary										
Overall	-0.31	0.02	-5.73	<0.001	-5.67	0.001	-4.19	0.01	-3.46	0.02
Survivor no CRT	-0.35	-0.15	-6.10	<0.001	-6.17	<0.001	-4.42	0.008	-3.76	0.02
Survivor with CRT	-0.22	0.46	-4.85	0.009	-4.50	0.007	-3.55	0.07	-2.61	0.08

SES, socioeconomic status; P=p-value for comparison of the difference between survivor and sibling without adjustment for SES in the model, referenced to non-Hispanic white survivor and sibling difference; P*=p-value for comparison of the difference between survivor and sibling with an added adjustment for SES in the model, referenced to non-Hispanic White survivor and sibling difference. Adjusted for household income, education level and insurance status in addition to sex, age at follow-up, year at diagnosis, methotrexate exposure (intravenous and intrathecal), corticosteroid exposure, any CTCAE grade 3-4 chronic medical condition. Outcomes which became non-significant after the addition of current SES are bolded and italicized.

Supplemental Table 3. CCSS questionnaire completion by race/ethnicity for survivors, includes death prior to follow-up.

Characteristic	Survivors, n(%)								
	White, NH			Black, NH			Hispanic		
	Baseline n=19,926	Deceased n=2,215	Follow-up n=12,287	Baseline n=1,521	Deceased n=199	Follow-up n=600	Baseline n=1,814	Deceased n=181	Follow-up n=821
Sex									
Male	10666 (53.5)	1312 (58.9)	6139 (49.8)	798 (52.5)	120 (61.7)	298 (48.8)	955 (54.0)	111 (61.4)	373 (45.4)
Female	9260 (46.5)	903 (41.1)	6148 (50.2)	723 (47.5)	79 (38.3)	302 (51.2)	859 (46.0)	70 (38.6)	448 (54.6)
Age at diagnosis (years)									
0-4	7750 (41.2)	602 (28.9)	4709 (40.2)	639 (43.9)	59 (29.7)	240 (41.1)	765 (45.1)	52 (28.7)	308 (39.5)
5-9	4397 (23.2)	482 (22.5)	2733 (23.3)	367 (25.0)	55 (27.7)	134 (23.9)	449 (26.3)	45 (26.4)	233 (29.3)
10-14	4290 (19.8)	537 (23.1)	2663 (20.2)	324 (20.0)	53 (27.2)	142 (22.5)	347 (16.8)	46 (24.7)	156 (17.8)
15-20	3489 (15.7)	594 (25.5)	2182 (16.3)	191 (11.0)	32 (15.4)	84 (12.5)	253 (11.8)	38 (20.2)	124 (13.4)
Year of diagnosis									
1970-79	5886 (26.3)	1020 (43.6)	3842 (28.4)	255 (14.6)	65 (31.3)	114 (16.7)	304 (13.8)	52 (27.3)	155 (16.4)
1980-89	8091 (38.8)	837 (37.7)	5313 (41.6)	596 (35.9)	74 (38.3)	274 (42.3)	634 (31.9)	69 (37.8)	322 (36.7)
1990-99	5949 (35.0)	358 (18.7)	3132 (30.1)	670 (49.5)	60 (30.5)	212 (41.0)	876 (54.3)	60 (34.8)	344 (46.9)
Age at evaluation (years)									
<25	10274 (53.5)	734 (34.1)	2649 (22.6)	834 (56.9)	72 (35.9)	150 (26.3)	980 (57.0)	66 (36.1)	201 (26.6)
25-34	7539 (36.9)	998 (45.1)	5738 (48.2)	558 (35.5)	90 (44.9)	297 (49.5)	658 (34.8)	79 (44.8)	407 (49.7)
35-44	2067 (9.3)	461 (19.9)	3402 (25.5)	129 (7.6)	37 (19.2)	142 (22.6)	173 (8.0)	35 (18.6)	196 (21.9)
45-54	46 (0.2)	22 (0.9)	498 (3.7)	0 (0.0)	0 (0.0)	11 (1.6)	3 (0.1)	1 (0.5)	17 (1.8)
≥55									
Cancer diagnosis									
Acute lymphoblastic leukemia	5045 (33.5)	474 (25.6)	3216 (33.0)	290 (29.7)	28 (17.7)	133 (31.4)	524 (41.6)	41 (26.5)	232 (37.8)
Acute myeloid leukemia	648 (2.9)	61 (2.6)	421 (3.1)	67 (3.8)	8 (3.9)	20 (2.9)	96 (4.3)	4 (2.1)	48 (5.1)
Other leukemia	232 (1.0)	51 (2.2)	118 (0.9)	22 (1.3)	5 (2.4)	5 (0.7)	28 (1.3)	8 (4.2)	13 (1.4)
Astrocytoma	2177 (9.7)	283 (12.1)	1279 (9.4)	137 (7.8)	26 (12.5)	54 (7.9)	169 (7.6)	24 (12.6)	87 (9.2)
Medulloblastoma, PNET	782 (3.5)	112 (4.8)	468 (3.5)	62 (3.5)	12 (5.8)	34 (5.0)	93 (4.2)	19 (10.0)	29 (3.1)
Other CNS tumors	598 (2.7)	99 (4.2)	331 (2.4)	44 (2.5)	3 (1.4)	23 (3.4)	58 (2.6)	12 (6.3)	21 (2.2)
Hodgkin lymphoma	2534 (11.3)	405 (17.3)	1569 (11.6)	164 (9.4)	29 (14.0)	67 (9.8)	210 (9.5)	27 (14.2)	106 (11.2)
Non-Hodgkin lymphoma	1630 (7.3)	124 (5.3)	992 (7.3)	120 (6.9)	14 (6.7)	45 (6.6)	124 (5.6)	8 (4.2)	54 (5.7)
Kidney tumors	1665 (7.4)	77 (3.3)	1097 (8.1)	267 (15.2)	20 (9.6)	96 (14.1)	150 (6.8)	10 (5.3)	67 (7.1)
Neuroblastoma	1534 (6.9)	101 (4.3)	864 (6.4)	107 (6.1)	15 (7.2)	32 (4.7)	129 (5.8)	7 (3.7)	57 (6.0)
Soft tissue sarcoma	1423 (6.4)	165 (7.1)	919 (6.8)	127 (7.3)	21 (10.1)	48 (7.1)	90 (4.1)	9 (4.7)	38 (4.0)
Ewing sarcoma	647 (2.9)	138 (5.9)	377 (2.8)	7 (0.4)	1 (0.5)	3 (0.4)	32 (1.4)	3 (1.6)	16 (1.7)
Osteosarcoma	920 (4.1)	117 (5.0)	575 (4.2)	107 (6.1)	17 (8.2)	40 (5.9)	107 (4.8)	9 (4.7)	51 (5.4)
Other bone tumors	91 (0.4)	8 (0.3)	61 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	4 (0.2)	0 (0.0)	2 (0.2)

Supplemental Table 3 continued. CCSS questionnaire completion by race/ethnicity for survivors, includes death prior to follow-up.

Cranial radiation (maxTD)										
None	12537 (70.6)	1087 (58.1)	7902 (70.3)	886 (72.6)	85 (56.7)	341 (68.7)	1154 (74.4)	89 (59.4)	536 (73.1)	
>0-<20† Gy	1685 (10.3)	147 (8.8)	1121 (10.5)	103 (11.2)	11 (10.9)	49 (13.6)	139 (9.7)	5 (4.8)	64 (9.9)	
≥20 Gy	3725 (19.1)	627 (33.2)	2341 (19.1)	217 (16.2)	46 (32.3)	101 (17.8)	291 (15.9)	57 (35.8)	134 (17.1)	
Intravenous methotrexate										
No	14297 (72.8)	1538 (75.0)	9060 (73.9)	917 (65.9)	119 (76.7)	361 (64.5)	1243 (71.5)	127 (77.2)	584 (72.8)	
Yes	4120 (27.2)	421 (25.0)	2530 (26.1)	321 (34.1)	31 (23.3)	134 (35.5)	398 (28.5)	32 (22.8)	175 (27.2)	
Intrathecal methotrexate										
No	12459 (60.0)	1434 (69.3)	7756 (60.7)	897 (61.6)	114 (71.9)	347 (60.6)	1075 (53.3)	119 (70.7)	503 (57.4)	
Yes	5958 (40.0)	525 (30.7)	3834 (39.3)	341 (38.4)	36 (28.1)	148 (39.4)	566 (46.7)	40 (29.3)	256 (42.6)	
Systemic corticosteroid										
No	10726 (52.9)	1108 (53.9)	6697 (53.4)	819 (57.3)	107 (67.6)	301 (52.6)	947 (49.4)	91 (55.6)	436 (51.3)	
Yes	7691 (47.1)	851 (46.1)	4893 (46.6)	419 (42.7)	43 (32.4)	194 (47.4)	694 (50.6)	68 (44.4)	323 (48.7)	
Health insurance status										
Yes	15905 (86.9)		11021 (90.3)	1054 (78.2)		478 (79.5)	1247 (73.9)		696 (85.8)	
No	2321 (13.1)		1182 (9.7)	299 (21.8)		116 (20.5)	403 (26.1)		123 (14.2)	
Household income (\$‡)										
<20,000	1696 (10.2)		1036 (10.1)	370 (31.5)		115 (27.6)	261 (18.1)		105 (15.8)	
20-59,999	5245 (30.1)		3134 (30.1)	449 (37.9)		198 (40.7)	586 (39.1)		271 (39.9)	
60-99,999	4781 (26.9)		2839 (26.3)	235 (19.8)		93 (19.0)	335 (21.9)		160 (23.2)	
≥100,000	5882 (32.8)		3741 (33.5)	140 (10.9)		63 (12.8)	311 (20.9)		158 (21.1)	
Educational attainment										
<High school graduate	832 (9.1)		327 (3.4)	94 (15.2)		22 (5.5)	103 (13.1)		38 (5.9)	
High school graduate	1610 (17.3)		1219 (12.4)	177 (26.0)		90 (18.6)	185 (22.0)		91 (15.2)	
College graduate	6798 (73.6)		8067 (84.3)	392 (58.9)		336 (75.9)	515 (64.9)		490 (79.0)	
Employment										
Unemployed	2315 (15.6)		2383 (19.2)	319 (29.4)		176 (28.8)	324 (25.1)		209 (25.0)	
Employed/student	13178 (84.4)		9904 (80.8)	786 (70.6)		424 (71.2)	1020 (74.9)		612 (75.0)	

Reported values for time-varying demographic (age at evaluation) and socioeconomic outcomes (employment, education, income and insurance status) were based on time of reported survey completion (baseline or follow-up).

Percentages were weighted to account for under-sampling of acute lymphoblastic leukemia survivors in latter era (1987–1999)

†Direct cranial radiation doses (not including stray/scatter). ‡Adjusted to 2016-dollar value. NH=non-Hispanic; maxTD=maximum tumor dose

Supplemental Table 4. CCSS questionnaire completion by race/ethnicity for siblings.

Characteristic	Siblings, n(%)					
	White, NH		Black, NH		Hispanic	
	Baseline n=4,370	Follow-up n=2,882	Baseline n=149	Follow-up n=70	Baseline n=214	Follow-up n=103
Sex						
Male	2097 (48.0)	1311 (45.5)	58 (38.9)	31 (44.0)	93 (43.5)	44 (43.0)
Female	2273 (52.0)	1571 (54.5)	91 (61.1)	39 (56.0)	121 (56.5)	59 (57.0)
Age at evaluation (years)						
<25	1809 (41.4)	544 (18.9)	66 (44.3)	21 (30.0)	102 (47.7)	29 (28.2)
25-34	1625 (37.2)	1076 (37.3)	47 (31.5)	25 (35.7)	79 (36.9)	43 (41.7)
35-44	836 (19.1)	963 (33.4)	35 (23.5)	20 (28.6)	28 (13.1)	25 (24.3)
45-54	99 (2.3)	288 (10.0)	1 (0.7)	4 (5.7)	5 (2.3)	5 (4.9)
≥55	1 (0.0)	11 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)
Health insurance status						
Yes	3906 (90.5)	2630 (91.6)	123 (84.2)	61 (87.1)	172 (82.7)	83 (81.4)
No	412 (9.5)	241 (8.4)	23 (15.8)	9 (12.9)	36 (17.3)	19 (18.6)
Household income (\$‡)						
<20,000	221 (5.6)	125 (4.8)	23 (19.7)	5 (10.6)	16 (8.5)	8 (9.1)
20-59,999	1018 (25.7)	555 (21.2)	33 (28.2)	14 (29.8)	59 (31.4)	23 (26.1)
60-99,999	1106 (27.9)	673 (25.7)	34 (29.1)	15 (31.9)	50 (26.6)	32 (36.4)
≥100,000	1619 (40.8)	1266 (48.3)	27 (23.1)	13 (27.7)	63 (33.5)	25 (28.4)
Educational attainment						
<High school graduate	93 (3.8)	36 (1.5)	6 (7.3)	0 (0.0)	7 (6.6)	1 (1.4)
High school graduate	365 (14.8)	253 (10.8)	21 (25.6)	10 (20.4)	15 (14.2)	8 (10.8)
College graduate	2004 (81.4)	2048 (87.6)	55 (67.1)	39 (79.6)	84 (79.2)	65 (87.8)
Employment						
Unemployed	429 (10.8)	325 (11.3)	27 (21.8)	8 (11.4)	36 (18.9)	15 (14.5)
Employed/student	3545 (89.2)	2557 (88.7)	97 (78.2)	62 (88.6)	154 (81.1)	88 (85.4)

Reported values for time-varying demographic (age at evaluation) and socioeconomic outcomes (employment, education, income and insurance status) were based on time of reported survey completion (baseline or follow-up).

‡Adjusted to 2016-dollar value. NH=non-Hispanic.